Illumina Launches DRAGEN™ 4.2 for More Accurate and Comprehensive Genomic Coverage

Empower More Applications and Discoveries

2023The year marks the integration and launch of Illumina's industry-leadingDRAGENThe Fifth Anniversary of the Software

San Diego, California, USAJuly 12, 2023PR Newswire -- July 11, 2023, Illumina (NASDAQ: ILMN), a global leader in genomics and chip technology, announced the launch of the latest version of DRAGEN™ software for analyzing next-generation sequencing data. DRAGEN 4.2 combines its award-winning accuracy with its highly acclaimed flexibility and scalability to enable efficient workflows and derive meaningful insights from genomic data.

Rami Mehio, Vice President of Software and Informatics at Illumina, stated: "DRAGEN 4.2 will further enhance the accuracy and comprehensiveness of secondary analysis. On the fifth anniversary of DRAGEN joining Illumina, we are witnessing the rapid adoption of genomics in clinical, precision medicine, and research fields. DRAGEN’s ability to execute high-quality, fast, precise, and comprehensive NGS analysis workflows makes it an ideal choice for supporting healthcare and research. We remain committed to continuously and comprehensively improving the detection and interpretation of whole-genome variants, providing support for clinicians and researchers in understanding human health."

DRAGEN v4.2 improves the identification of causative variants in genetic diseases, drug discovery, and analysis pipelines related to population genomics, specifically including:

In the latest feature, the brand-new targeted detection program can further enhance the ability to treat cardiovascular diseases and identify blood types. Fritz Sedlazeck from the Human Genome Sequencing Center at Baylor College of Medicine in Houston, an early partner of DRAGEN 4.2, noticed this potential.

Sedlazeck stated: "DRAGEN 4.2 is a significant leap forward in genomic analysis. In addition to SNV detection, this software can also detect various types of variants, promoting comprehensive analysis of genomic samples. These new features include new approaches for treating cardiovascular diseases, such as detection procedures for LP(a). Research on this gene has been ongoing for over forty years, and these capabilities provide us with deeper insights. Now, we can achieve new discoveries through this reliable tool."

Lipoprotein(a), or LP(a), is an emerging potential risk factor with clinical significance associated with cardiovascular disease. Targeting the detection of genetic variants related to high levels of LP(a) can further advance clinical research and contribute to the development of detection and treatment methods.

Before this version was released, DRAGEN 4.1 had been integrated intoNovaSeq X SeriesIn the sequencing platform, this series is Illumina's latest and the most powerful sequencer in the company’s product family history.

For more information, please visitDRAGEN Special Page。

AboutDRAGEN

As the industry-leading secondary genomic analysis software, Illumina DRAGEN’s continuous innovation has set new standards for the accuracy and efficiency of bioinformatics analysis. DRAGEN analysis inReproductive systemAndSomatic cellIt leads in the accuracy of variant detection, which has been proven in industry challenges from PrecisionFDA. DRAGEN supports multiple access points, from standalone servers to Illumina's cloud solutions and specific onboard sequencers, simplifying sequencing data collection and analysis.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Our business is subject to the following important factors, which could cause actual results to differ materially from those projected in any forward-looking statement: (i) the inherent challenges in developing, manufacturing, and launching new products and services; (ii) customer acceptance and satisfaction with new products and services; (iii) legislative, regulatory, and economic developments, as well as other factors detailed in our filings with the U.S. Securities and Exchange Commission, including our most recent Forms 10-K and 10-Q, or information disclosed during previously announced public conference calls, for which dates and times have been announced in advance. We have no obligation to update these forward-looking statements, nor do we intend to assess or confirm analysts' related expectations, or provide interim reports or updates for the current quarter.

About Illumina

Illumina, Inc. is committed to advancing and inspiring genomics to continuously improve human health. In 2023, Illumina celebrated its 25th anniversary. Over 25 years of innovation have established us as a global leader in sequencing and array technologies, providing specialized services to customers in research, clinical, and applied markets worldwide. Our products are widely used in life sciences, oncology, reproductive health, agriculture, and other emerging fields. For more information, please visitwww.illumina.com.cnOr follow the Illumina WeChat Official Account.